Is This Small-Cap Biotech a Buy After Its Second Approved Gene Therapy?

·4-min read
Is This Small-Cap Biotech a Buy After Its Second Approved Gene Therapy?

Despite recently getting its third drug approved, Bluebird Bio (NASDAQ: BLUE) only has a $1.7 billion market cap. Bluebird Bio already had a multiple myeloma CAR T-cell therapy, Abecma, approved earlier this year, and now it has not one, but two gene therapy approvals for rare genetic diseases in the EU. On July 21, the rapidly maturing biotech received EU approval for its latest gene therapy, Skysona, for cerebral adrenoleukodystrophy (CALD).

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting